Cardiovascular conditions are as common in those with demyelinating diseases (multiple sclerosis, neuromyelitis optica and transverse myelitis)
https://www.researchgate.net/profile/Pa ... elitis.pdf
Background: Cardiovascular conditions are associated with poorer outcomes in multiple sclerosis (MS). Whether
the burden of cardiovascular conditions differs between those with demyelinating disease and unaffected controls
is not clear. The objective of this study is to investigate the burden and age of onset of cardiovascular
conditions in a US population with MS, neuromyelitis optica spectrum disorder (NMOSD), or transverse myelitis
(TM) to unaffected controls adjusting for likely confounders.
Methods: Using a case-control study design, we compared the burden of self-reported diabetes mellitus type 2,
heart disease, hyperlipidemia, and hypertension in cases with MS (N=1,548), NMOSD (N=306), and TM
(N=145) to controls (N=677), adjusting for demographics, smoking history, obesity, family history of individual
cardiovascular conditions, and presence of other cardiovascular conditions. The age of onset for individual
cardiovascular conditions were also compared between cases and controls.
Results: MS cases were 48% more likely to have ever had hypertension than controls (p=0.01). The prevalence
of other cardiovascular conditions did not differ across cases and controls. There were also no differences in the
age of cardiovascular disease onset between cases and controls.
Conclusion: Cardiovascular conditions are as common in those with demyelinating diseases compared to unaffected
individuals, with hypertension being more common among those with MS.
Cardiovascular conditions are as common in those with MS
A forum to discuss Chronic Cerebrospinal Venous Insufficiency and its relationship to Multiple Sclerosis.
Return to “Chronic Cerebrospinal Venous Insufficiency (CCSVI)”
Jump to
- Multiple Sclerosis
- ↳ General Discussion
- ↳ Introductions
- ↳ Drug Pipeline
- ↳ Regimens
- ↳ Undiagnosed
- ↳ MS Etiology and Pathogenesis
- Treatments
- ↳ Chronic Cerebrospinal Venous Insufficiency (CCSVI)
- ↳ Low Dose Naltrexone
- ↳ Tysabri (Antegren, Natalizumab)
- ↳ Copaxone
- ↳ Glatopa
- ↳ Avonex
- ↳ Rebif
- ↳ Betaseron
- ↳ Plegridy
- ↳ Novantrone
- ↳ Aimspro
- ↳ Diet
- ↳ Stem Cells
- ↳ Antibiotics
- ↳ Campath (Lemtrada, Alemtuzumab)
- ↳ Gene Therapy
- ↳ Natural Approach
- ↳ Biotin (Qizenday, Cerenday, MD1003)
- ↳ Coimbra High-Dose Vitamin D Protocol
- ↳ Statins
- ↳ Tcelna (Tovaxin)
- ↳ Revimmune (Cyclophosphamide, Cytoxan)
- ↳ Medical Devices
- ↳ Rituxan (Rituximab)
- ↳ Ocrevus (Ocrelizumab)
- ↳ Kesimpta (Ofatumumab)
- ↳ Briumvi (Ublituximab-xiiy)
- ↳ General Medications
- ↳ Tecfidera (BG-12, Dimethyl fumarate)
- ↳ Vumerity (Diroximel fumarate)
- ↳ Bafiertam (Monomethyl fumarate)
- ↳ Gilenya
- ↳ Aubagio (Teriflunomide)
- ↳ Mayzent (Siponimod)
- ↳ Zeposia (Ozanimod)
- ↳ Ponvory (Ponesimod)
- ↳ Mavenclad (Cladribine)
- ↳ Ampyra (Dalfampridine)
- ↳ Medical Marijuana
- ↳ Sativex
- ↳ Chiropractic Treatment
- Life
- ↳ Daily Life
- ↳ Veterans and MS
- ↳ Trigeminal Neuralgia in MS
- ↳ Reading Nook
- ↳ Humor
- ↳ Shopping
- ↳ Friends and Family
- ↳ Mental & Spiritual Health
- ↳ Exercise and Physical Therapy
- ↳ Under 25 with MS
- ↳ MS in the Golden Years
- ↳ Parenting Kids With MS
- ↳ Parents with MS
- ThisIsMS.com
- ↳ Site Support
- ↳ Suggestions